Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 9/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL15145961 | 0.97 | DRD2 (0.57) | ACHEBACE1DRD2TDP1SIGMAR1 | |
| SCHEMBL31596990 | 0.95 | DRD2 (0.58) | ACHEBACE1DRD2TDP1SIGMAR1 | |
| SCHEMBL9127008 | 0.94 | DRD2 (0.60) | ACHEBACE1DRD2TDP1SIGMAR1 | |
| SCHEMBL4572542 | 0.92 | DRD2 (0.60) | ACHEBACE1DRD2TDP1SIGMAR1 | |
| SCHEMBL8254760 | 0.92 | DRD2 (0.64) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL485945 | 0.90 | DRD2 (0.55) | ACHEBACE1DRD2TDP1MEN1 | |
| SCHEMBL7220892 | 0.90 | DRD2 (0.55) | ACHEBACE1DRD2TDP1MEN1 | |
| SCHEMBL4024516 | 0.89 | DRD2 (0.56) | ACHEBACE1DRD2TDP1MEN1 | |
| SCHEMBL18851206 | 0.88 | DRD2 (0.56) | ACHEBACE1DRD2TDP1SIGMAR1 | |
| Biphenyl SCHEMBL28784863 | 0.88 | DRD2 (0.62) | ACHEBACE1DRD2SIGMAR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| EP-1341785-B1 | HYDROLYSIS OF R(R*,R*)-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4- [(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE | TEVA PHARMA (IL) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008110351-A2 | USE OF (R) AND (S)-2-ARYL-PROPIONIC ACID DERIVATIVES AS ANTISEPTIC AGENTS | DOMPE' PHA.R.MA S.P.A. (IT) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-20040242670-A1 | Process for preparation of amorphous atorvastatin calcium | SEBASTIAN SONNY (IN) | 2004-12-02 | — | — | US | disclosed |
| US-6476235-B2 | CHEMICAL INTERMEDIATE; ANTICHOLESTEROL AGENTS, ANTILIPEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020099224-A1 | Hydrolysis of [R (R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099224-A1 | Hydrolysis of [R (R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide | HMGCR, DHCR7, GRHPR | ACHE 1671/4885BACE1 357/4885DRD2 3911/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | ACHE 4816/4885BACE1 3894/4885DRD2 4808/4885 |
| US-20040242670-A1 | Process for preparation of amorphous atorvastatin calcium | HMGCR, CACNA1S, SREBF1 | ACHE 1989/4885BACE1 481/4885DRD2 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.